DK165358C - Renset Bordetella pertussis antigen, vaccine indeholdende et sådant antigen og fremgangsmåde til isolering af et sådant ant - Google Patents
Renset Bordetella pertussis antigen, vaccine indeholdende et sådant antigen og fremgangsmåde til isolering af et sådant ant Download PDFInfo
- Publication number
- DK165358C DK165358C DK198502089A DK208985A DK165358C DK 165358 C DK165358 C DK 165358C DK 198502089 A DK198502089 A DK 198502089A DK 208985 A DK208985 A DK 208985A DK 165358 C DK165358 C DK 165358C
- Authority
- DK
- Denmark
- Prior art keywords
- antigen
- vaccine
- pertussis
- amino acid
- supernatant
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 41
- 241000588832 Bordetella pertussis Species 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 20
- 239000000427 antigen Substances 0.000 title claims description 44
- 108091007433 antigens Proteins 0.000 title claims description 44
- 102000036639 antigens Human genes 0.000 title claims description 44
- 239000000463 material Substances 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 22
- 102000030621 adenylate cyclase Human genes 0.000 claims abstract description 16
- 108060000200 adenylate cyclase Proteins 0.000 claims abstract description 16
- 201000005702 Pertussis Diseases 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000002955 isolation Methods 0.000 claims abstract 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 13
- 239000004471 Glycine Substances 0.000 claims description 12
- 238000004458 analytical method Methods 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 239000004220 glutamic acid Substances 0.000 claims description 6
- 238000001155 isoelectric focusing Methods 0.000 claims description 6
- 230000036039 immunity Effects 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 2
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 abstract description 8
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000000499 gel Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 229940066827 pertussis vaccine Drugs 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 239000003547 immunosorbent Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 229940030156 cell vaccine Drugs 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 4
- 101710154643 Filamentous hemagglutinin Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 206010043376 Tetanus Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 206010013023 diphtheria Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000012149 elution buffer Substances 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 101710116435 Outer membrane protein Proteins 0.000 description 3
- 108010081690 Pertussis Toxin Proteins 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 229960003983 diphtheria toxoid Drugs 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229960004906 thiomersal Drugs 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- FBEHFRAORPEGFH-UHFFFAOYSA-N Allyxycarb Chemical compound CNC(=O)OC1=CC(C)=C(N(CC=C)CC=C)C(C)=C1 FBEHFRAORPEGFH-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 101710110818 Dermonecrotic toxin Proteins 0.000 description 2
- 206010061217 Infestation Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229960005097 diphtheria vaccines Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 229960002766 tetanus vaccines Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- APUIQTDTBPKWKE-RNPGEKFLSA-N (2r,6s)-6-[[(4r)-4-[[(2s)-2-[2-[[(1r,2s,3r,4r,5r)-4-acetamido-2-[(2s,3r,4r,5s,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6,8-dioxabicyclo[3.2.1]octan-3-yl]oxy]propanoylamino]propanoyl]amino]-4-carboxybutanoyl]amino]-2-amino-7-[[(2r)-2-am Chemical compound O([C@@H]1[C@H]2CO[C@H](O2)[C@H](NC(C)=O)[C@H]1OC(C)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](CCC[C@@H](N)C(O)=O)C(=O)NC(=O)[C@H](N)C)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O APUIQTDTBPKWKE-RNPGEKFLSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100028218 Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 108010038061 Chymotrypsinogen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000724276 Homo sapiens Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 1 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000002791 glucosyl group Chemical class C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000007973 glycine-HCl buffer Substances 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003345 natural gas Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000005789 organism growth Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8412207 | 1984-05-12 | ||
| GB848412207A GB8412207D0 (en) | 1984-05-12 | 1984-05-12 | Antigenic preparations |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| DK208985D0 DK208985D0 (da) | 1985-05-10 |
| DK208985A DK208985A (da) | 1985-11-13 |
| DK165358B DK165358B (da) | 1992-11-16 |
| DK165358C true DK165358C (da) | 2000-11-06 |
Family
ID=10560891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198502089A DK165358C (da) | 1984-05-12 | 1985-05-10 | Renset Bordetella pertussis antigen, vaccine indeholdende et sådant antigen og fremgangsmåde til isolering af et sådant ant |
Country Status (13)
| Country | Link |
|---|---|
| US (8) | US5648080A (fi) |
| EP (1) | EP0162639B1 (fi) |
| JP (3) | JPH07116053B2 (fi) |
| AT (1) | ATE61937T1 (fi) |
| CA (1) | CA1253073A (fi) |
| DE (1) | DE3582272D1 (fi) |
| DK (1) | DK165358C (fi) |
| ES (1) | ES8802275A1 (fi) |
| FI (1) | FI81262C (fi) |
| GB (1) | GB8412207D0 (fi) |
| LU (1) | LU90203I2 (fi) |
| NL (1) | NL980006I1 (fi) |
| NO (2) | NO165478C (fi) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8412207D0 (en) * | 1984-05-12 | 1984-06-20 | Wellcome Found | Antigenic preparations |
| FR2597344B1 (fr) * | 1986-04-16 | 1989-06-23 | Merieux Inst | Perfectionnement au procede de purification d'antigenes proteiques de bacteries appartenant au genre bordetella, en vue de l'obtention d'un vaccin acellulaire. |
| US4762710A (en) * | 1986-06-16 | 1988-08-09 | The United States Of America As Represented By The Department Of Health And Human Services | Novel method of preparing toxoid by oxidation and metal ions |
| SE455946B (sv) * | 1986-10-20 | 1988-08-22 | Trion Forskning & Utveckling | Nya pertussistoxin-polypeptider och antigener samt testsatser, vacciner och intradermala hudtestkompositioner |
| FR2606789B1 (fr) * | 1986-11-17 | 1991-05-31 | Pasteur Institut | Preparations d'adenylate cyclase purifiees, procede d'obtention de ces preparations et leurs applications biologiques |
| EP0267998A1 (en) * | 1986-11-17 | 1988-05-25 | Institut Pasteur | Means for protecting against bordetella infections and toxic processes |
| CA1337859C (en) * | 1987-04-24 | 1996-01-02 | Masashi Chazono | Method for culturing bordetella pertussis, a pertussis toxoid and a pertussis vaccine |
| US5139776A (en) * | 1987-04-24 | 1992-08-18 | The Research Foundation For Microbial Diseases Of Osaka University | Method for culturing Bordetella pertussis, a pertussis toxoid and a pertussis vaccine |
| DE3855442T2 (de) * | 1988-04-19 | 1997-03-06 | Inst Nat Sante Rech Med | Verfahren zur Gewinnung von Schutzantigenen gegen Bordetella-Infektionen und toxische Prozesse |
| EP0338170A1 (en) * | 1988-04-19 | 1989-10-25 | Institut Pasteur | Immunoprotective antigenic protein against pathogenic bacteria |
| GB8910570D0 (en) | 1989-05-08 | 1989-06-21 | Wellcome Found | Acellular vaccine |
| FR2646776B1 (fr) | 1989-05-12 | 1994-06-03 | Pasteur Institut | Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella |
| DE69018926T2 (de) * | 1989-09-04 | 1995-08-24 | Wellcome Found | Vakzine gegen Bordetella. |
| US5276142A (en) * | 1989-12-11 | 1994-01-04 | American Cyanamid Company | Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis |
| US6197548B1 (en) | 1990-04-02 | 2001-03-06 | Medeva Pharma Limited | Transformed Pichia expressing the pertactin antigen |
| GB9007657D0 (en) * | 1990-04-04 | 1990-05-30 | Connaught Lab | Purification of a pertussis outer membrane protein(omp69) |
| EP0484621A3 (en) * | 1990-07-11 | 1992-08-26 | American Cyanamid Company | Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens |
| GB9021004D0 (en) * | 1990-09-27 | 1990-11-07 | Wellcome Found | Acellular vaccines |
| US6444211B2 (en) | 1991-04-03 | 2002-09-03 | Connaught Laboratories, Inc. | Purification of a pertussis outer membrane protein |
| GB9304399D0 (en) * | 1993-03-04 | 1993-04-21 | Smithkline Beecham Biolog | Novel process |
| FR2728170A1 (fr) * | 1994-12-15 | 1996-06-21 | Pasteur Institut | Vaccin de type acellulaire anti-bordetella |
| FR2736064B1 (fr) | 1995-06-30 | 1997-09-05 | Pasteur Institut | Epitopes protecteurs de l'adenyl cyclase-hemolysine(ac-hty). leur application au traitement ou a la prevention des infections par bordetella |
| ZA981370B (en) * | 1997-02-20 | 1998-09-07 | Cerberus Developments Bv | Method and apparatus for continuous flow isoelectric focusing for purifying biological substances |
| GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
| US8916173B2 (en) | 2013-03-08 | 2014-12-23 | Crucell Holland B.V. | Acellular pertussis vaccine |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3141824A (en) * | 1961-05-19 | 1964-07-21 | Lilly Co Eli | Pertussis antigen |
| US3395219A (en) * | 1964-12-11 | 1968-07-30 | Merck & Co Inc | Process for production of pertussis antigen |
| US3465078A (en) * | 1965-10-21 | 1969-09-02 | Sydney Z Spiesel | Method of recovering antigens from bordetella pertussis cells |
| FR2047886A1 (en) * | 1969-06-30 | 1971-03-19 | Merieux Inst | Non-toxic anti-whooping cough vaccine |
| FR2393065A1 (fr) * | 1977-05-31 | 1978-12-29 | Merieux Inst | Procede de separation de lipides d'endotoxines bacteriennes et notamment d'endotoxine de bordetella pertussis |
| GB2014452B (en) * | 1978-02-17 | 1982-07-21 | Secr Social Service Brit | Producing cell envelope preparations |
| EP0004137B1 (en) * | 1978-02-17 | 1981-11-11 | National Research Development Corporation | Immunogenic cell envelope preparations |
| JPS5750925A (en) * | 1980-09-12 | 1982-03-25 | Takeda Chem Ind Ltd | Preparation of pertussis toxoid |
| US4551429A (en) * | 1983-09-15 | 1985-11-05 | American Home Products Corporation | Stimulation of antigen production by Bordetella pertussis |
| US5237052A (en) * | 1984-05-12 | 1993-08-17 | Burroughs Wellcome Company | Antigenic preparations and isolation of such preparations |
| GB8412207D0 (en) * | 1984-05-12 | 1984-06-20 | Wellcome Found | Antigenic preparations |
| US4705686A (en) * | 1986-05-09 | 1987-11-10 | American Cyanamid | Process for the preparation of acellular Bordetalla pertussis vaccine |
| EP0267998A1 (en) * | 1986-11-17 | 1988-05-25 | Institut Pasteur | Means for protecting against bordetella infections and toxic processes |
| FR2606789B1 (fr) * | 1986-11-17 | 1991-05-31 | Pasteur Institut | Preparations d'adenylate cyclase purifiees, procede d'obtention de ces preparations et leurs applications biologiques |
| GB8807860D0 (en) * | 1988-04-05 | 1988-05-05 | Connaught Lab | Pertussis vaccine |
| US5101014A (en) * | 1989-02-10 | 1992-03-31 | United States Of America | Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis |
| GB8910570D0 (en) * | 1989-05-08 | 1989-06-21 | Wellcome Found | Acellular vaccine |
| US5276142A (en) * | 1989-12-11 | 1994-01-04 | American Cyanamid Company | Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis |
| GB9007416D0 (en) * | 1990-04-02 | 1990-05-30 | Wellcome Found | Expression of heterologous protein in yeast |
| GB9007657D0 (en) * | 1990-04-04 | 1990-05-30 | Connaught Lab | Purification of a pertussis outer membrane protein(omp69) |
| IT1248735B (it) * | 1990-06-21 | 1995-01-26 | Sclavo Spa | Vaccini acellulari contro la pertosse |
| EP0484621A3 (en) | 1990-07-11 | 1992-08-26 | American Cyanamid Company | Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens |
-
1984
- 1984-05-12 GB GB848412207A patent/GB8412207D0/en active Pending
-
1985
- 1985-05-10 CA CA000481336A patent/CA1253073A/en not_active Expired
- 1985-05-10 JP JP60099413A patent/JPH07116053B2/ja not_active Expired - Lifetime
- 1985-05-10 ES ES543026A patent/ES8802275A1/es not_active Expired
- 1985-05-10 FI FI851859A patent/FI81262C/fi not_active IP Right Cessation
- 1985-05-10 AT AT85303302T patent/ATE61937T1/de active
- 1985-05-10 DK DK198502089A patent/DK165358C/da not_active IP Right Cessation
- 1985-05-10 DE DE8585303302T patent/DE3582272D1/de not_active Revoked
- 1985-05-10 NO NO851878A patent/NO165478C/no not_active IP Right Cessation
- 1985-05-10 EP EP85303302A patent/EP0162639B1/en not_active Expired - Lifetime
-
1994
- 1994-03-21 US US08/210,458 patent/US5648080A/en not_active Expired - Lifetime
- 1994-05-11 US US08/240,814 patent/US5438120A/en not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/478,046 patent/US6048700A/en not_active Expired - Lifetime
- 1995-06-07 US US08/470,590 patent/US6127151A/en not_active Expired - Lifetime
-
1997
- 1997-08-01 NO NO1997010C patent/NO1997010I1/no unknown
-
1998
- 1998-01-27 NL NL980006C patent/NL980006I1/nl unknown
- 1998-01-28 LU LU90203C patent/LU90203I2/fr unknown
-
1999
- 1999-06-17 US US09/334,690 patent/US6210685B1/en not_active Expired - Fee Related
- 1999-06-30 US US09/343,399 patent/US20020150595A1/en not_active Abandoned
- 1999-07-07 JP JP11193416A patent/JP2000072690A/ja active Pending
- 1999-07-07 JP JP11193312A patent/JP2000053585A/ja active Pending
-
2002
- 2002-09-16 US US10/243,930 patent/US20030077294A1/en not_active Abandoned
- 2002-12-27 US US10/329,946 patent/US20030108572A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20020150595A1 (en) | 2002-10-17 |
| FI81262C (fi) | 1990-10-10 |
| JP2000072690A (ja) | 2000-03-07 |
| JP2000053585A (ja) | 2000-02-22 |
| DK165358B (da) | 1992-11-16 |
| US6127151A (en) | 2000-10-03 |
| ES8802275A1 (es) | 1988-05-01 |
| JPH07116053B2 (ja) | 1995-12-13 |
| NO165478B (no) | 1990-11-12 |
| GB8412207D0 (en) | 1984-06-20 |
| EP0162639A2 (en) | 1985-11-27 |
| US5648080A (en) | 1997-07-15 |
| US20030077294A1 (en) | 2003-04-24 |
| US20030108572A1 (en) | 2003-06-12 |
| US5438120A (en) | 1995-08-01 |
| CA1253073A (en) | 1989-04-25 |
| FI81262B (fi) | 1990-06-29 |
| ATE61937T1 (de) | 1991-04-15 |
| ES543026A0 (es) | 1988-05-01 |
| JPS60246321A (ja) | 1985-12-06 |
| NL980006I1 (nl) | 1998-04-01 |
| LU90203I2 (fr) | 1998-04-06 |
| NO851878L (no) | 1985-11-13 |
| FI851859A0 (fi) | 1985-05-10 |
| EP0162639B1 (en) | 1991-03-27 |
| US6210685B1 (en) | 2001-04-03 |
| US6048700A (en) | 2000-04-11 |
| DK208985A (da) | 1985-11-13 |
| EP0162639A3 (en) | 1988-02-03 |
| NO165478C (no) | 1991-02-20 |
| NO1997010I1 (no) | 1997-08-25 |
| FI851859L (fi) | 1985-11-13 |
| DE3582272D1 (de) | 1991-05-02 |
| DK208985D0 (da) | 1985-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK165358C (da) | Renset Bordetella pertussis antigen, vaccine indeholdende et sådant antigen og fremgangsmåde til isolering af et sådant ant | |
| CN101203605B (zh) | 革兰氏阴性菌的lps的脱酰基化 | |
| EP0914153B1 (en) | Multivalent dtp-polio vaccines | |
| Di Tommaso et al. | Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing | |
| EP0432203A1 (en) | Legionellosis vaccines and methods for their production | |
| JPS6051120A (ja) | 単純ヘルペスサブユニットワクチン | |
| AU641711B2 (en) | Process for purification of a 69 000 dalton antigenetic protein from bordetella pertussis | |
| KR101617464B1 (ko) | Ｉｐｖ―ｄｐｔ 백신 | |
| Novotny et al. | Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine | |
| JP2999480B2 (ja) | 百日咳感染及び毒性過程に対する保護抗原を得るための方法 | |
| JPS61111695A (ja) | Ｂ型肝炎ビールス又はｂ型肝炎ビールス成分からのｄｎａフラグメント、ポリペプチド及びオリゴペプチド、組み換えｄｎａ分子、ｄｎａベクター、エシエリヒア・コリｋ１２変異体、ポリペプチドの製法、ｂ型肝炎ビールス疾患に対する接種物質、モノクロナール抗体ｍａ１８／７、マウス雑種細胞ｇｏ１ａ１８／７‐１並びにモノクロナール抗体ｍａ１８／７の製法 | |
| US5237052A (en) | Antigenic preparations and isolation of such preparations | |
| DK172329B1 (da) | Polydisperse, native Pseudomonas-flagella(H)-antigener (FAg) i polymer form og fremgangsmåde til deres udvinding | |
| GB2062463A (en) | Babesiosis vaccine | |
| EP0002645B1 (en) | Antigenic complex from neisseria gonorrhoeae, process and vaccine | |
| JPH0272200A (ja) | 百日咳トキソイドワクチン | |
| JPS59110626A (ja) | Ｂ−オリゴマ−含有百日咳ワクチンおよびその製造方法 | |
| BRPI0202458B1 (pt) | Processo de obtenção de vacina pertussis acelular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PPF | Opposition filed | ||
| PUP | Patent expired |